TELEMETRY READOUT / MITOCHONDRIAL-DERIVED PEPTIDE
MOTS-c peptide is a mitochondrial-derived signal studied for AMPK activation and metabolic homeostasis.
Sixteen amino acids encoded inside the mitochondrial 12S rRNA. The mechanism is well mapped in animals and cells; the human evidence is thin and observational. This site logs both, cited to source.
The short version
Here is the MOTS-c peptide in plain words. It is a tiny protein — sixteen building blocks long — that your own mitochondria (the parts of a cell that make energy) build from a gene inside their own DNA. When researchers give extra MOTS-c to mice, it flips on a master fuel-sensing switch called AMPK, which helps muscle take up sugar and burn fat. In animals it improved insulin response, boosted running capacity, and curbed weight gain. The catch: almost all of that evidence is from mice and cells. No completed human trial has tested whether it does the same in people.
What Is MOTS-c?
MOTS-c is a 16-amino-acid peptide with the sequence MRWQEMGYIFYPRKLR, encoded by a short open reading frame inside the mitochondrial 12S ribosomal RNA gene (MT-RNR1) [1]. That origin makes it a mitochondrial-derived peptide (MDP) — a small bioactive peptide written into the mitochondrial genome itself rather than the nuclear DNA that codes for most proteins. It is one member of a small family that also includes humanin and the SHLPs; MOTS-c is distinct from those in both sequence and primary action [4].
The peptide is endogenous: it is detectable in human plasma and skeletal muscle, and its levels rise with exercise and shift with age and metabolic state [2]. Its molecular weight is 2174.61 Da (CAS 1627580-64-6), and the 16-residue sequence is highly conserved across mammals — a signal that evolution has kept it for a reason [1].
What MOTS-c does, mechanistically, is the heart of its story. Its best-characterized action is inhibition of the folate cycle (the one-carbon reactions a cell uses to build the purine bases of DNA), which causes the intermediate AICAR to pile up and switch on AMPK — the enzyme a cell uses as its low-fuel alarm [1]. Activated AMPK shifts metabolism toward energy production and glucose uptake, primarily in skeletal muscle. The full chain is detailed on the MOTS-c AMPK mechanism page.
What the Literature Has Established
The founding result is metabolic. In the 2015 Cell Metabolism paper that named the peptide, MOTS-c prevented diet-induced obesity and high-fat-diet-induced insulin resistance in mice, and identified skeletal muscle as its primary target organ and AMPK as the downstream effector [1]. Chronic dosing ran at 0.5 mg/kg/day by intraperitoneal injection over roughly eight weeks.
The exercise result is the most striking. In a 2021 Nature Communications study, exogenous MOTS-c (15 mg/kg) significantly increased treadmill running capacity in aged mice (P = 0.000002), along with grip strength and gait, and confirmed that endurance exercise itself induces endogenous MOTS-c [2]. That pairing — exercise raises the peptide, and the peptide reproduces exercise adaptations — is why MOTS-c is studied as a candidate exercise mimetic.
The mechanistic landmark is that MOTS-c does not stay in the mitochondrion. Under metabolic stress it translocates to the nucleus and regulates nuclear gene expression in an AMPK-dependent way, including antioxidant-response genes through the transcription factor NRF2 [3] — the first demonstration that a mitochondrial-encoded peptide can perform retrograde signaling. A 2024 study went further and identified casein kinase 2 (CK2) as a direct binding target of MOTS-c [9].
The honest counterweight: every one of those findings is from cells or animals. The human record is observational — circulating MOTS-c tracks with insulin resistance, exercise, and, in one 2024 cohort, mortality risk in dialysis patients [10] — but no completed interventional human efficacy trial of exogenous MOTS-c exists [4].
What This Site Is
MOTS-c Chemical is an independent editorial readout of the published MOTS-c literature. It logs what the peer-reviewed studies actually measured — the dose, the species, the route, the outcome — and flags, in plain sight, where the evidence stops. The mechanism is tracked on the MOTS-c AMPK mechanism page; the studies and MOTS-c benefits reported in the literature are read on the research page; the MOTS-c dosage in the research literature is presented as research context only; the regulatory picture — including the MOTS-c legal status and FDA 503A category question — is read straight from audited FDA sources. Reader questions are answered in the frequently asked questions about MOTS-c. It is not a clinic and it does not sell anything.